Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
February 18, 2015 3:18 AM
Antibodies 2015, 4(1), 12-33; doi:10.3390/antib4010012ReviewCell-Free Synthesis Meets Antibody Production: A ReviewMarlitt Stech and Stefan Kubick * + Authors' affiliationReceived: 2 December 2014 / Accepted: 13 January 2015 / Published: 26 January 2015(This article belongs to the Special Issue Antibody Constructs)
Sign up to comment
Krishan Maggon 's curator insight,
February 9, 2015 6:46 AM
Drug Resistance Updates Volume 18, January 2015, Pages 36–46 Antibody-targeted drugs and drug resistance—Challenges and solutionsLeeRon Shefet-Carasso, Itai Benhar, doi:10.1016/j.drup.2014.11.001 |
Krishan Maggon 's curator insight,
February 9, 2015 6:51 AM
Highlights
• Bispecific antibodies (BsAb) bind 2 distinct antigens or epitopes on the same antigen. • Antibody domain structure has been exploited to make >60 alternative BsAb formats. • 2 BsAb are approved for therapy and >30 BsAb are in clinical development. • A common clinical application of BsAb is retargeting T cells to kill tumor cells. • Other clinical uses of BsAb include dual blockade of different disease mediators. Molecular Immunology Available online 27 January 2015 In Press, Corrected Proof — Note to users Review Alternative molecular formats and therapeutic applications for bispecific antibodies ☆Christoph Spiess , Qianting Zhai , Paul J. Carter, Show moredoi:10.1016/j.molimm.2015.01.003Get rights and contentUnder a Creative Commons license |